Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Nov 18, 2023 2:53pm
231 Views
Post# 35742756

RE:RE:RE:RE:RE:comgrats

RE:RE:RE:RE:RE:comgratsI have to agree.

Any fear of Dan should lead you to exit this stock and look for something more comfortable for your investment dollar.

I think if you look at the make-up of the development team and the clinical team, you will realize they are not the same people.  There is room for OTENA and for other drug development.  That being said, I absolutely prefer the development team to work on OTENA chronic and very high pain drugs before we move elsewhere.

And - I am not suggesting they push new molecules through until they have the cash to push.

I can only say ... we've been waiting patiently and accumulating below 60 cents for a very long time.  We've been doing this without fear of the CEO or the Board.  We are well focused on the strategic manouvering that got us to a better place in H2S technology ... as we learned the secrets of the liver.

Also, we are well aware that the potential far outweighs the limited excitement from management and we understand why they chose that route.

Success isn't about the buy/sell games played on the markets - and as such - the fluctuating share price.  It's about building a value for the shareholders.  Not today but in the future.

And yes ... value comes from drug success - not hype.  It comes from the ability to pivot when you need to pivot.  You have to realize how difficult H2S is to figure out and how blind this team has been while navigating H2S terrain.

If you get all that - then you have an idea of what's happening at ATE.
<< Previous
Bullboard Posts
Next >>